

Chen Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2608515/publications.pdf>

Version: 2024-02-01

12
papers

211
citations

1306789

7
h-index

1281420

11
g-index

12
all docs

12
docs citations

12
times ranked

235
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of Dipyridamole Analogues with Enhanced Metabolic Stability for the Treatment of Idiopathic Pulmonary Fibrosis. <i>Molecules</i> , 2022, 27, 3452.	1.7	0
2	Discovery of effective phosphodiesterase 2 inhibitors with antioxidant activities for the treatment of Alzheimer's disease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 41, 128016.	1.0	6
3	Design, synthesis and biological evaluation of novel pyrazolopyrimidone derivatives as potent PDE1 inhibitors. <i>Bioorganic Chemistry</i> , 2021, 114, 105104.	2.0	4
4	Discovery of Novel Selective and Orally Bioavailable Phosphodiesterase-1 Inhibitors for the Efficient Treatment of Idiopathic Pulmonary Fibrosis. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 7867-7879.	2.9	23
5	Discovery and Optimization of Chromone Derivatives as Novel Selective Phosphodiesterase 10 Inhibitors. <i>ACS Chemical Neuroscience</i> , 2020, 11, 1058-1071.	1.7	7
6	Design, synthesis and evaluation of pyrazolopyrimidinone derivatives as novel PDE9A inhibitors for treatment of Alzheimer's disease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127254.	1.0	6
7	Validation of Phosphodiesterase-10 as a Novel Target for Pulmonary Arterial Hypertension via Highly Selective and Subnanomolar Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 3707-3721.	2.9	26
8	Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 4218-4224.	2.9	15
9	Optimization of Chromeno[2,3- <i>c</i>]pyrrol-9(2 <i>H</i>)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structure-Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8468-8473.	2.9	21
10	Discovery of Novel Phosphodiesterase-2A Inhibitors by Structure-Based Virtual Screening, Structural Optimization, and Bioassay. <i>Journal of Chemical Information and Modeling</i> , 2017, 57, 355-364.	2.5	40
11	Discovery of Novel Pyrazolopyrimidinone Derivatives as Phosphodiesterase 9A Inhibitors Capable of Inhibiting Butyrylcholinesterase for Treatment of Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2017, 8, 2522-2534.	1.7	29
12	Discovery and Optimization of Chromeno[2,3- <i>c</i>]pyrrol-9(2 <i>H</i>)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 6622-6637.	2.9	34